logo

XERS

Xeris Biopharma·NASDAQ
--
--(--)
--
--(--)
4.03 / 10
Netural

Xeris Biopharma's fundamental metrics are fair (4.0/10). Key strengths include a healthy 44.1% year-over-year revenue growth and positive interest-coverage ratio (0.52). However, factors like Days sales outstanding (61.7) and negative valuation spreads temper the outlook. Overall, the company demonstrates solid operational growth but faces liquidity and leverage challenges that warrant monitoring.

Fundamental(4.03)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value-0.83
Score3/3
Weight18.09%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value44.11
Score2/3
Weight1.55%
1M Return1.11%
Days sales outstanding
Value61.70
Score2/3
Weight1.57%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight14.43%
1M Return8.45%
Net income-Revenue
Value-2.98
Score2/3
Weight14.44%
1M Return8.45%
PB-ROE
Value2.42
Score2/3
Weight17.99%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value0.52
Score2/3
Weight-1.44%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value44.11
Score2/3
Weight0.60%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight18.60%
1M Return10.15%
Cash-MV
Value-0.77
Score2/3
Weight14.18%
1M Return8.41%
Is XERS fundamentally strong?
  • XERS scores 4.03/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -5.88% net margin, -74.37 P/E ratio, -1350.91 P/B ratio, and 76.74% earnings growth, these metrics solidify its Netural investment rating.